Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hans Thalsgaard Schambye is active.

Publication


Featured researches published by Hans Thalsgaard Schambye.


Journal of Pharmacological and Toxicological Methods | 2009

Assessing low-dose gentamicin-induced kidney injury in rats by analysis of urine

Anders Nykjaer; Hans Thalsgaard Schambye; Anders Hjelholt Pedersen; Henning Nielsen

INTRODUCTION Gentamicin is an important aminoglycoside antibiotic used in clinics to combat infections from especially gram negative bacteria. A frequent side-effect of aminoglycoside antibiotics is a kidney injury consisting of necrosis of proximal tubular cells. It is important both in clinics and in research directed to eliminate or ameliorate this side-effect that a method is available for detection of injury at an early stage. METHODS We have therefore compared the sensitivity of four methods currently used in animal models to assess kidney injury induced by aminoglycoside antibiotics by applying them to the analysis of urine from male rats treated with low doses of gentamicin. RESULTS Excretion of phospholipids was significantly increased in contrast to excretion of N-acetyl-beta-glucosaminidase (NAG), neutrophil gelatinase-associated lipocalin (NGAL) and protein. Assessment of phospholipiduria thus is the more sensitive noninvasive way to monitor initial renal injury induced by aminoglycoside antibiotics. A protocol is given for the serial analysis of urinary phospholipids allowing a considerable number of determinations to be carried out in the course of 2-3 days. DISCUSSION It is well known that all four considered methods do detect kidney damage induced in rats by high gentamicin doses far above doses used in clinics. The present investigation shows that only the analysis of the urinary phospholipids will detect damage induced by low doses of gentamicin. The method is relevant for animal model studies but will require considerable and innovative development for use in clinics.


Archive | 2006

G-csf conjugates

Torben Lauesgaard Nissen; Kim Vilbour Andersen; Christian Karsten Hansen; Jan Moeller Mikkelsen; Hans Thalsgaard Schambye


The Journal of Clinical Endocrinology and Metabolism | 2003

Glycosylation of an N-Terminal Extension Prolongs the Half-Life and Increases the in Vivo Activity of Follicle Stimulating Hormone

Signe Perlman; Bart van den Hazel; Jesper Christiansen; Sanne Gram-Nielsen; Claus Bekker Jeppesen; Kim Vilbour Andersen; Torben Halkier; Sigurd Okkels; Hans Thalsgaard Schambye


Archive | 2001

G-CSF polypeptides and conjugates

Torben Lauesgaard Nissen; Kim Vilbour Andersen; Christian Karsten Hansen; Jan Moller Mikkelsen; Hans Thalsgaard Schambye


Archive | 2003

Interferon-beta variants and conjugates

Anders Hjelholt Pedersen; Hans Thalsgaard Schambye; Kim Vilbour Andersen; Claus Bornaes; Poul Baad Rasmussen


Archive | 2000

Improved lysosomal enzymes and lysosomal enzyme activators

Jens Sigurd Okkels; Anne Dam Jensen; Torben Halkier; Rikke Bolding Jensen; Hans Thalsgaard Schambye


Archive | 2001

Conjugates of follicle stimulating hormones

Hans Thalsgaard Schambye; Kim Vilbour Andersen; Den Hazel Bart Van; Jesper Christiansen; Claus Bekker Jeppesen


Archive | 2002

Adiponectin fragments and conjugates

Poul Baad Rasmussen; Kim Vilbour Andersen; Anders Hjelholt Pedersen; Hans Thalsgaard Schambye; Torben Halkier; Are Bogsnes


Archive | 2006

USE OF A GLP-1 MOLECULE FOR TREATMENT OF BILIARY DYSKINESIA AND/OR BILIARY PAIN/DISCOMFORT

Tina Geritz Nielsen; Henrik Nilsson; Christian Hansen; Hans Thalsgaard Schambye


Archive | 2006

PHARMACEUTICAL PREPARATIONS OF A GLP-1 MOLECULE AND AN ANTI-EMETIC DRUG

Hans Thalsgaard Schambye; Henrik Nilsson; Christian Hansen

Collaboration


Dive into the Hans Thalsgaard Schambye's collaboration.

Researchain Logo
Decentralizing Knowledge